|
TYPES
Anaplastic Large Cell | AIDS-related | Childhood NHL | CLL/SLL | CNS | Cutaneous | Diffuse Large Cell | EBV-Related | Follicular | Hodgkins | Large B-Cell | Mantle Cell | Marginal Zone (MALT) | MDS | Mediastinal | NHL |
T-Cell | Transformed to aggressive | Waldenström’s
Lookup Trials by subtype and treatment status PAL
or select from menu:
|
|
or Clinical Trials of Interest | Search Tools | Pipeline
|
Anaplastic
Large Cell
Related Abstracts:
Adult PubMed
Childhood PubMed
T/null cell, primary cutaneous or systemic PubMed
|
Investigational treatments for:
.gif) |
All studies | CD30+ specified
|
|
Recurrent ALC
|
|
AIDS/HIV -related
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies
|
|
Newly diagnosed or untreated
|
|
Recurrent
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies
|
|
Newly diagnosed or untreated
|
|
Recurrent
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies | Randomized
|
|
Newly diagnosed or untreated
|
|
Recurrent
|
|
|
Related Abstracts:
PubMed
ASH 2009
|
Investigational treatments (updated Jan 2010)
|
All Studies
|
|
Previously untreated CNS lymphoma (first line)
|
|
Recurrent / Refractory
|
|
Search also using TrialCheck.org |
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All Studies
|
|
Newly diagnosed or untreated
|
|
Recurrent
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
Newly diagnosed or untreated DLBCL *
|
With CNS involvement *
|
|
|
Recurrent DLBCL all recruiting studies *
|
|
|
Related Abstracts:
PubMed
ASCO
Medscape
|
Investigational treatments for:
|
All studies
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All newly diagnosed or untreated
|
|
All recurrent
|
Excluding chemotherapy (by request)
|
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies
|
|
Newly diagnosed or untreated
|
|
Recurrent | Lymphocyte predominant
|
|
|
|
Investigational treatments for:
|
All studies
|
|
Newly diagnosed or untreated (fixed 11-18)
|
|
Recurrent
|
Excluding chemotherapy (by request)
|
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies
|
|
Bexxar regimens (by request)
|
|
Newly Diagnosed or untreated
|
Excluding chemotherapy (by request)
|
|
|
Recurrent
|
Excluding chemotherapy (by request)
|
|
|
|
Related Abstracts:
PubMed
Medscape
|
Investigational treatments for:
|
All studies
|
|
Newly diagnosed or untreated | including adult NHL unspecified
|
|
Recurrent
|
|
MDS
Myelodysplastic Syndrome
Related Abstracts:
PubMed
ASCO
Medscape
|
Investigational treatments for:
|
MDS (Myelodysplastic Syndrome) -
a complication of treatment for lymphoma
|
|
|
Related Abstracts:
ASH 2009
|
Investigational treatments for:
|
All treatments (check for aliases - too few results)
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies
|
|
NEW All studies (excluding Stem Cell Transplant) *
|
|
Newly diagnosed or untreated
|
|
Recurrent
|
By Subtype (by request):
|
Anaplastic Large Cell type:
Newly diagnosed or previously untreated AND Recurrent
|
|
Angioimmunoblastic type | with stem cell transplant
|
|
Cutaneous T-cell lymphomas *
|
|
NK Cell
|
|
PTCL (Peripheral T-cell Lymphoma) *
|
By investigational agents:
|
Anti-Tac for Tac-expressing NHL, including T-cell NHL)
|
|
Daclizumab (t-cell lymphomas)
|
|
Denileukin diftitox - ONTAK (IL-2/diphtheria toxin fusion protein)
Possible mechanisms: "The IL-2 portion of the molecule targets the lymphoma cells by binding to the IL-2 receptor on the plasma membrane, and upon endocytosis, the diphtheria toxin is delivered to the lymphoma cells. Common side effects are nausea and vomiting, fever and flu-like symptoms. Other significant side effects include the cytokine release syndrome and vascular leak syndrome"- ncbi.nlm.nih.gov/books
 Topic Search on this agent: PubMed
|
|
Depsipeptide (histone deacetylase inhibitor)
Possible mechanisms: induction of apoptosis, cell cycle arrest, and differentiation via the modulation of gene expression by histone acetylation
Topic Search on this agent: PubMed
|
|
Immune therapies
|
|
Pralatrexate
Possible mechanisms: "Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate carrier type 1 (RFC-1). Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against TCL." - PMID: 16988580
Topic Search on this agent: PubMed
|
|
Radioimmunotherapy
|
|
SAHA (Suberoylanilide Hydroxamic Acid)
Possible mechanisms: "SAHA treatment caused an accumulation of acetylated histones (H2B, H3, and H4), an increase of p21(WAF1) and bax proteins, a decrease of Stat6 and phospho-Stat6 proteins, and activation of caspase-3 in CTCL cells." - PMID: 16297208
Topic Search on this agent: PubMed
|
|
T-cell antibodies (biological agents that bind to receptors expressed on t-cells)
|
SGN-30 (anti-CD30)
|
|
|
|
|
Investigational treatments for indolent lymphomas
transformed to aggressive:
|
All studies
|
|
CLL (transformed Chronic Lymphocytic Lymphoma/Leukemia)
|
|
Follicular
|
|
Radioimmunotherapy
|
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
All studies
|
|
newly diagnosed or untreated
|
|
recurrent
|
|
